Supreme Court takes up Monsanto Roundup case that could reshape pesticide liability nationwide

The Supreme Court heard oral arguments Monday in a case that could shut down thousands of state-level cancer lawsuits against the maker of Roundup, and the Trump administration's Justice Department lined up squarely on Monsanto's side, drawing sharp criticism from Make America Healthy Again allies who expected a different fight.

At issue is whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state failure-to-warn claims against pesticide manufacturers whose labels have been approved by the Environmental Protection Agency. Monsanto, now owned by Bayer, asked the high court to overturn a $1.25 million verdict won by Missouri plaintiff John Durnell, who alleged decades of Roundup exposure caused his non-Hodgkin lymphoma.

The case carries enormous financial stakes. Breitbart reported that Bayer has faced more than 100,000 Roundup claims and set aside roughly $16 billion to settle cases. In February, Monsanto and plaintiffs announced a separate $7.25 billion settlement agreement covering current and future claims from people exposed to Roundup who developed non-Hodgkin lymphoma.

A ruling for Monsanto would not merely resolve one Missouri verdict. It could effectively bar similar lawsuits across the country, a prospect that alarmed MAHA-aligned health advocates and pleased agricultural industry groups in nearly equal measure.

Justices appear split on federal preemption

The justices appeared divided during Monday's arguments, the Associated Press reported. Some justices expressed sympathy for Bayer's federal-preemption argument, while others pressed on whether states would be left powerless when new scientific evidence emerges about a pesticide's risks.

Chief Justice John Roberts posed a pointed question about the gap between EPA's slow regulatory process and evolving research. "Throughout that long process, in response to information that suggests there is a risk that's not on the label, the states cannot do anything?" Roberts asked.

Justice Brett Kavanaugh pushed back from the other direction, questioning whether a patchwork of state requirements could undermine the federal regulatory scheme. "Do you think it's uniformity when each state can require different things?" Kavanaugh asked, as the Washington Times reported.

That tension, between federal uniformity and state-level accountability, sits at the heart of the dispute. The Supreme Court has been handling a string of high-stakes cases this term, and the Roundup fight may prove among the most consequential for both public health law and agricultural regulation.

The legal arguments

Monsanto's position rests on FIFRA's language barring states from imposing labeling or packaging requirements "in addition to or different from" those set by the EPA. Because the EPA has not linked glyphosate to cancer, Monsanto argues, federal law "thus requires Monsanto to use product labels that do not warn of a supposed link between glyphosate and cancer." Allowing state juries to find otherwise, the company contends, would directly conflict with the federal regulatory framework.

Durnell's legal team countered with a different reading of the same statute. His brief cited a provision stating that EPA approval of a pesticide and its label should not "be construed as a defense" against violating FIFRA. In other words, federal registration does not grant blanket immunity.

Durnell's attorneys argued further that even if federal law prevented Monsanto from adding a cancer warning to Roundup's EPA-approved labels, "FIFRA would still prohibit Monsanto from distributing or selling Roundup if the judiciary finds its labels misleading or inadequate." That framing would preserve the right of injured plaintiffs to seek redress in state courts without requiring the EPA to act first.

The Trump administration's Justice Department filed briefs agreeing with Monsanto and was expected to argue in support of the company during Monday's session. That alignment put the administration on the side of federal preemption, and on a collision course with the MAHA movement that helped build its health-conscious political brand.

MAHA allies voice frustration with the White House

President Trump pledged to "Make America Healthy Again" and installed Robert F. Kennedy Jr. as Health and Human Services secretary. But the Justice Department's decision to back Monsanto left MAHA-aligned figures openly questioning whether the administration's health commitments extend to pesticide policy.

David Murphy, founder of advocacy group United We Eat and a former finance director of Kennedy's presidential campaign, did not mince words. He told The Hill:

"People are very disappointed in the Trump administration, especially the White House."

Murphy went further, framing the administration's posture as a political miscalculation with electoral consequences:

"They've unfortunately made this calculation, and they're going to have to live with it. It'll be one of many things that costs them the midterms this year."

A Politico poll found that 50 percent of self-identified MAHA followers described limiting pesticide use as a core principle of the movement. That number suggests the administration's legal posture in this case runs against the instincts of a constituency it actively courted.

Ahead of Monday's arguments, MAHA movement figures and left-wing environmental advocates rallied outside the court in an unusual bipartisan display. Rep. Thomas Massie, a Kentucky Republican, and Rep. Chellie Pingree, a Maine Democrat, both joined the demonstration, a pairing that underscores how the Roundup case cuts across familiar partisan lines.

The Court has taken up several major Trump administration policy disputes this term. But the Monsanto case is unusual because the friction runs not between the administration and its opponents, but between the administration and some of its own supporters.

Industry sees broader consequences

Agricultural industry groups warned that a ruling against Monsanto could destabilize the market for crop-protection products far beyond glyphosate. Elizabeth Burns-Thompson, executive director of the Modern Ag Alliance, told reporters:

"It really puts a risk on the availability of not just glyphosate moving forward, but really all products."

That concern reflects a fear among manufacturers that if state-level failure-to-warn claims survive federal preemption, any EPA-approved pesticide could face open-ended jury liability, regardless of what the federal label says. For farmers and agribusiness, the uncertainty is real. For plaintiffs' attorneys, so is the potential payday.

Bayer CEO Bill Anderson framed the combination of the Supreme Court case and the February settlement as a way forward. Newsmax reported his statement: "The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty."

Congress, meanwhile, has not waited for the justices. House Republicans included language in their version of the farm bill that would protect pesticides from certain lawsuits, a legislative backstop that could moot parts of the legal fight regardless of how the Court rules.

That legislative effort tracks with the broader pattern of Congress stepping in after major Supreme Court decisions to reassert its own policy preferences through statute.

What remains unresolved

Environmental advocates framed the case in terms of basic accountability. Patti Goldman, a senior attorney at Earthjustice, said the outcome will determine whether injured people can seek justice at all:

"This case will determine whether people who are harmed by pesticides can have access to courts to seek redress."

Goldman added that state-court lawsuits serve as a check on industry behavior:

"It is one of the critical ways that people can hold pesticide companies accountable, and then that creates incentives for them to change their products to be safer or to take harmful pesticides off the market."

The EPA's position, that glyphosate is not likely carcinogenic when used as directed, remains the federal government's official stance. Other assessments, including from international bodies, have reached different conclusions. That scientific disagreement is precisely what makes the preemption question so charged: if the EPA is wrong, or slow to update its findings, a ruling for Monsanto could leave injured Americans with no legal remedy at all.

The Supreme Court's willingness to intervene in high-profile cases this term has drawn attention from across the political spectrum. The Roundup case may not generate the same cable-news heat as some of the Court's other docket items, but its consequences for ordinary Americans, farmers, cancer patients, and anyone who uses a product with an EPA-approved label, could be far more direct.

A decision is expected before the Court's term ends. When it arrives, it will answer a straightforward question that Washington has dodged for years: Does an EPA label shield a company from accountability, even when the science is still being fought over?

If the answer is yes, the federal government had better be right about glyphosate. Because the people who got sick won't have anywhere else to go.